Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method and Kit for Detection of Dengue Virus

---
identifier: "/us/fr/02-1643"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method and Kit for Detection of Dengue Virus"
title_number: 0
title_name: "Federal Register"
section_number: "02-1643"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method and Kit for Detection of Dengue Virus"
positive_law: false
currency: "2002-01-23"
last_updated: "2002-01-23"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "02-1643"
document_type: "notice"
publication_date: "2002-01-23"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "67 FR 3168"
fr_volume: 67
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method and Kit for Detection of Dengue Virus

**AGENCY:**

U.S. Army Medical Research and Materiel Command, DOD.

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,190,859 entitled “Method and Kit for Detection of Dengue Virus” issued 02/20/01. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models. Uses of the inactivated dengue virus for detecting antibodies to dengue and kits therefore are also described.

Luz D. Ortiz,

Army Federal Register Liaison Officer.